Transcription of No.15-32 2015 エーザイ株式会社 - eisai.co.jp
1 CEO 4mg 10mg ( ) 5 20 III SELECT 1 II 208 13,000 29,000 VEGFR FGFR RET KIT PDGFR VEGFR FGFR RET VEGFR2 X V 2 2015 2 2015 3 III II 2015 5 20
2 1. 1) 4mg 10mg 2) 3) 4) 1 1 24mg 5) 4mg 3, 10mg 9, 6) 4mg 20 PTP10 2 10mg 20 PTP10 2 7) 2. (VEGFR) VEGFR1 VEGFR2 VEGFR3 FGFR FGFR1 FGFR2 FGFR3 FGFR4 PDGFR PDGFR KIT RET RTK VEGFR FGFR RET VEGFR2 X V 2 2015 2 2015 3 European Medicines Agency EMA Committee for Medicinal Products for Human Use CHMP )
3 III II 3. V 2 I V I II X V 4. SELECT 1 SELECT Study of E7080 LEnvatinib in Differentiated Cancer of the Thyroid 13 VEGF 1 24mg 1 1 = 2:1 III (progression free survival PFS CR PR SFJ Pharma Ltd.)
4 100 392 40 PFS < vs 99 = < vs CR 4 0 40 5. 208 208 RR-DTC MTC ATC 2012 9 2014 6 43 RR-DTC 23 MTC 9 ATC 11 RR-DTC MTC ATC PR RR-DTC MTC ATC SD 40 ( ) ( ) ( ) ( ) ( ) 6.
5 Differentiated Thyroid Cancer: DTC 95 3 5 1 2 1 Schlumberger M, et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N. Engl. J. Med. 2015; 372, 621 630 2 Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett. 2015; 6, 89 94
![[エーザイ全社組織図] - eisai.co.jp](/cache/preview/f/b/6/d/b/5/a/0/thumb-fb6db5a086d3f9f33ede81b7595d5df1.jpg)
